TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline Menses for Participant Perceived Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inhibition of EGF tumor receptor tyrosine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: safety of L. frutescens
Endpoint domain: Adverse events/effects
Primary endpoint: Modification of sTie2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of weeks to create the final prosthesis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time the participants spend in the clinic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of hours spent to create the prosthetic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for surgery due to nonresolving small bowel obstruction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Are Considered Complete Responders at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Adverse Events (AEs), Treatment-Emergent AEs (TEAEs), and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain of local anaesthetic injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease activity of ulcerative colitis (modified Rachmilewitz score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: extent of colonic manifestation of ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Exercise Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients not meeting DGF criteria based on creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recanalization of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline peak sagittal plane angle of ankle, knee and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline value of sagittal plane angles for ankle, knee, hip, pelvis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline value of muscle maximal isometric strength for knee extensors and flexors, and hip adductors and abductors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Letters Gained of Best Corrected Visual Acuity Using ETDRS Protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of Hepatic decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Fugl-Meyer Assessment - Upper Extremity (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhage score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of Bevacizumab (Avastin)
Endpoint domain: Adverse events/effects
Primary endpoint: Fat oxidation points (FATmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fear of hypoglycemia score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quantity of BV-associated bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathogenic Clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concordance rate between UCAD and MFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of acute renal allograft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Circulating High Sensitivity C-Reactive Protein (Hs-CRP) Levels at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Density of Rotterdam Classification (ROC) Grade III/IV Strain Spots/10 Millimeter (mm) Within the Region of Interest (ROI) on IVUS Grey Scale Based Palpography at the End of Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Control of Allergic Rhinitis and Asthma Test (CARAT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in shoulder ER strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in shoulder IR ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in posterior shoulder mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in infraspinatus EMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: left and right ventricular volumes and masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time-intensity-curve upslopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in International Knee Documentation Committee subjective score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants withdrawing from treatment due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Young modulus to assess viscoelasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydraulic conductivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term reoccurrences of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gingival Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mRNA expression in leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of grade 4 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome at the test of cure (ToC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric Measurement Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection/Notification of Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Graft-versus-host Disease-free, Relapse-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline Fugl Meyer Assessment (FMA) upper extremities subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Active joint activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline Muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in BOP (bleeding on probing) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Mouth Plaque Score (FMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of extrahepatic deposition of microspheres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success of radioembolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of positive tests in smear negative malaria patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Procollagen type 1 n-terminal propeptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-terminal cross-linked type 1 collagen terminal peptide (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Binge Eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: satiation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: desire to eat dim sum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: desire to eat fruits or vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of neonates with hyaline membrane disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: biochemical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (Cl) for Doxorubicin and Cyclophosphamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glucose Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insulin Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of temporal artery thermometer measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of TEZ and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Patients With Any Suspected Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Total exposure of MetMAb (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants with any (serious and non-serious) Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with abnormal laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ANC recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Clinically Significant Pulse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Trends in Cardiac Telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in insulin resistance (HOMA index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose - Autologous Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose - Allogeneic Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphologic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Serum Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No. of participants who become responders or partial responders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients improving in Heart Failure Clinical Composite after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients improving in Heart Failure Clinical Composite after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 3 Year disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Direction of urinary bladder displacement during contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Drug Liking VAS Peak Effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Take Drug Again VAS Peak Effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Drug Value (SDV) Maximum Effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death From Regimen Toxicity or Opportunistic Infection
Endpoint domain: Mortality/survival
Primary endpoint: Death From GVHD
Endpoint domain: Mortality/survival
Primary endpoint: Successful Induction of Mixed Hematopoietic Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent egg reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Bowel Preparation Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline Sirtuin 1 serum protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients meeting evidence-based psychotherapy and pharmacotherapy initiation measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of completed evidence-based practice templates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of combination of prescriptions placed with the VA pharmacy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative pain remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative anal resting pressure at pain remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain and Impairment Relationship Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of GO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of AliveCor recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural times to achieve optimal sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in interferon gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dynamic tibiofemoral kinematics during activities of daily living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic tibiofemoral kinematics during sports activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Active Moiety, 9-hydroxy-risperidone and Risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional properties of cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Vineland Adaptive Behavior Scale (VABS-3)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Emotional/behavioral changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgeon satisfaction about haemostasis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of non-convulsive seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of Galectin-3 proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intraocular Pressure at 60 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intraocular Pressure at 90 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term efficacy and integrity of the EPICTM Nitinol Vascular Stent System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Identification of acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Blinded Visual Interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of adequate cleansing level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-ECT retrograde amnesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eating Disorders Examination Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacodynamic change on FLT-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet-monocyte complex formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet P-selectin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet fibrinogen binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-HBs Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Action duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of tumor samples with a useful OncotypeDx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cognitive testing outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Credibility Expectancy Questionnaire (CEQ) - Expectancy Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Home Practice Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systematic Assessment of Treatment-emergent Events-general Inquiry (SAFTEE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cognitive biomarkers assessed by DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lead-related complication-free rate at one-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic mean pacing thresholds at one-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of Contrast-induced acute kidney injury (CI-AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain at tenderpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation of isotopic measurement of GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in health attitudes and behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mucosa healing according to the MAYO score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization with resistant organism
Endpoint domain: Adverse events/effects
Primary endpoint: ECOG performance status over time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Rapid Upper Limb Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone height changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline of the score at the Yale - Brown Obsessive and Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Oxygen pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes